NCT00001269已完成1 期
Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 2
研究概览
简要总结
This is a phase I study to determine the maximal tolerated dose of IL-3 given alone or sequentially with GM-CSF following FLAC chemotherapy in metastatic breast cancer patients.
详细描述
Phase I study to determine the maximal tolerated dose of IL-3 given alone or sequentially with GM-CSF following FLAC chemotherapy.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract CancersBiliary Tract CancerNCT03291899King Faisal Specialist Hospital & Research Center13
Unknown
3 期
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer PatientsColorectal CarcinomaNCT02935764Fudan University164
已完成
3 期
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon CancerStage II Colon CancerStage III Colon CancerNCT00004931National Cancer Institute (NCI)2,472
Unknown
3 期
Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal CarcinomaEsophageal CarcinomaNCT01034683Taian Cancer Hospital120
已完成
3 期
Study Evaluating Isovorin in Colon CancerColon CancerNCT00195585Wyeth is now a wholly owned subsidiary of Pfizer650